Thalidomide-PEG3-NH2 is primarily utilized in the field of targeted drug delivery and proteolysis-targeting chimeras (PROTACs). Its structure allows it to act as a linker molecule, connecting therapeutic agents to specific target proteins. The thalidomide moiety is known for its ability to bind cereblon, an E3 ubiquitin ligase, which plays a crucial role in protein degradation pathways. This property makes it valuable in designing PROTACs, where it facilitates the recruitment of target proteins to the ubiquitin-proteasome system for degradation. The PEG3 spacer enhances solubility and reduces steric hindrance, improving the molecule's overall efficiency in biological systems. Additionally, the amine group (NH2) provides a reactive site for further conjugation with other molecules, enabling the development of complex drug delivery systems. This compound is particularly significant in cancer research, where it aids in the selective degradation of oncogenic proteins, offering a promising approach for targeted therapy.